Denali Therapeutics (DNLI) EBITDA (2017 - 2024)
Historic EBITDA for Denali Therapeutics (DNLI) over the last 8 years, with Q4 2024 value amounting to -$118.3 million.
- Denali Therapeutics' EBITDA fell 7.02% to -$118.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$421.4 million, marking a year-over-year decrease of 20603.58%. This contributed to the annual value of -$421.4 million for FY2024, which is 20603.58% down from last year.
- As of Q4 2024, Denali Therapeutics' EBITDA stood at -$118.3 million, which was down 7.02% from -$99.0 million recorded in Q3 2024.
- Denali Therapeutics' 5-year EBITDA high stood at $244.6 million for Q4 2020, and its period low was -$118.3 million during Q4 2024.
- Over the past 5 years, Denali Therapeutics' median EBITDA value was -$81.0 million (recorded in 2021), while the average stood at -$55.6 million.
- In the last 5 years, Denali Therapeutics' EBITDA surged by 55103.71% in 2020 and then plummeted by 15442.35% in 2024.
- Denali Therapeutics' EBITDA (Quarter) stood at $244.6 million in 2020, then plummeted by 131.57% to -$77.2 million in 2021, then decreased by 21.33% to -$93.7 million in 2022, then decreased by 26.11% to -$118.2 million in 2023, then dropped by 0.07% to -$118.3 million in 2024.
- Its EBITDA was -$118.3 million in Q4 2024, compared to -$99.0 million in Q3 2024 and -$100.4 million in Q2 2024.